Inovio's CELLECTRA® Electroporation Delivery Technology Powers Durable, Best-in-Class T-Cell Responses from HIV Vaccine in Human Study
Next-generation HIV vaccine achieves seven-fold increase (7% to 52%) in response rate of CD8 T-cells when delivered with electroporation; robust CD4 or CD8 T-cell responses observed in 89% of subjects
Results published in peer-reviewed Journal of Infectious Diseases
BLUE BELL, Pa., July 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX®-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio's proprietary CELLECTRA® electroporation delivery device. The studies were conducted by the HIV Vaccine Trials Network (HVTN). Inovio's HIV DNA vaccine together with the CELLECTRA device significantly increased the number of responders producing robust and durable CD4 and CD8 T-cell responses in humans. The observation of robust T-cell responses against distinct targeted diseases generated by different Inovio SynCon® DNA vaccines delivered using CELLECTRA electroporation technology have now been published in two respected peer-reviewed journals. These results are compelling because T-cells are considered critical to fighting cancers and chronic infectious diseases.
While Inovio previously released preliminary data from these two trials, this comparison and durability data was published in the peer-reviewed Journal of Infectious Diseases in the article, "Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid IL-12 and impact of intramuscular electroporation for delivery." The lead author was Dr. Spyros Kalams, who is Associate Professor of Medicine, Vanderbilt University Medical Center and principal investigator of Vanderbilt's HIV Vaccine Trials Unit for both clinical studies.